Citadel Advisors’s Tourmaline Bio TRML Stock Holding History

Citadel Advisors’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-5,900	Closed	-$89.7K	–	15131
2025 Q1	$89.7K	Sell	5,900 -6,000	-50%	-$96.2K	﹤0.01%	11617
2024 Q4	$241K	Buy	11,900 +2,900	+32%	+$73K	﹤0.01%	10103
2024 Q3	$231K	Sell	9,000 -7,700	-46%	-$129K	﹤0.01%	9846
2024 Q2	$215K	Sell	16,700 -6,000	-26%	-$96.5K	﹤0.01%	9777
2024 Q1	$520K	Buy	+22,700	New	+$800K	﹤0.01%	8304

Citadel Advisors's TRML Position: Q4 2025 in Review

Citadel Advisors sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 95,621 shares — an estimated $4.57M sold.

Citadel Advisors first reported a position in TRML in Q2 2021 and held it in 16 quarters. The position peaked at $40.7M in Q4 2021. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.

Citadel Advisors reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
Citadel Advisors sold 95,621 Tourmaline Bio shares in Q4 2025, an estimated $4.57M.
Citadel Advisors first reported a position in Tourmaline Bio in Q2 2021 and held it in 16 quarters.
Citadel Advisors's Tourmaline Bio position peaked at $40.7M in Q4 2021.
0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.